Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Common Equity: 2020-2023

Historic Common Equity for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to $147.0 million.

  • Therapeutics' Common Equity fell 44.73% to $95.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $95.5 million, marking a year-over-year decrease of 44.73%. This contributed to the annual value of $147.0 million for FY2023, which is 40.03% down from last year.
  • Latest data reveals that Therapeutics reported Common Equity of $147.0 million as of FY2023, which was down 40.03% from $245.2 million recorded in FY2022.
  • Therapeutics' 5-year Common Equity high stood at $245.2 million for FY2022, and its period low was $104.2 million during FY2020.
  • Moreover, its 3-year median value for Common Equity was $186.4 million (2021), whereas its average is $192.9 million.
  • As far as peak fluctuations go, Therapeutics' Common Equity surged by 78.90% in 2021, and later crashed by 40.03% in 2023.
  • Yearly analysis of 4 years shows Therapeutics' Common Equity stood at $104.2 million in 2020, then soared by 78.90% to $186.4 million in 2021, then spiked by 31.54% to $245.2 million in 2022, then slumped by 40.03% to $147.0 million in 2023.